GIBSON DUNN

Gibson Dunn Advises XOMA Royalty on Sale to Ligand Pharmaceuticals

Firm News | April 28, 2026

Gibson Dunn is advising XOMA Royalty on its sale to Ligand Pharmaceuticals Inc.

The firm's corporate team is led by partners Ryan Murr and Branden Berns and includes associate Evan Shepherd. Partners Pamela Lawrence Endreny and Rachel Kleinberg are advising on tax aspects. Partner Sean Feller is advising on benefits.

Related People

Ryan A. Murr

Branden C. Berns

Evan Shepherd

Pamela Lawrence Endreny

Rachel D. Kleinberg

Sean C. Feller

Related Capabilities

Mergers and Acquisitions

Life Sciences

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**